Bipolar Disorder Clinical Trial
— RechuteBPOfficial title:
Study of Predictor of Mood Relapse in Bipolar Disorders : Prospective, Clinical, Neuropsychological, Biological and Genetic Study
Verified date | June 2017 |
Source | Assistance Publique - Hôpitaux de Paris |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Study in 400 patients with bipolar disorder I or II, of relapse risk factors. The principal
objective of this research is to test the predictive value of core vulnerability dimensions
such as affective instability and emotional reactivity, measured by validated questionnaires
(AIM and ALS) on recurrence of affective major episode (depressed, hypomanic or manic)
during a 24 months prospective follow-up.
In addition, several arguments suggest that inter-individual variability in the risk of
relapse is influenced by genetic factors. In particular, the implication of such factors
have been demonstrated in rapid cycling or antidepressants induced mania. However, this has
never been tested in cohorts followed prospectively. Finally, the existence of
neuropsychological deficits in bipolar disorder is well documented and their role in the
risk of relapse is suspected. Yet the nature of these deficits, their origin and
evolutionary course remain poorly investigated. In summary, the secondary objectives of this
research are the study of the influence of these other clinical, neuropsychological and
genetic factors on the risk of relapse.
• Scientific rationale The dimensions of affective instability and emotional reactivity, are
considered core psychological and temperamental vulnerability dimensions to bipolar
disorder. Differences in levels of instability and reactivity may account for the
inter-individual variability observed in bipolar disorder in terms of risk of relapse. These
dimensions are measured using validated questionnaires (Affective Instability Measure (AIM)
and Affective Lability Scale (ALS)). Relapsing is defined as the occurrence of a depressive
episode, hypomanic, manic or mixed episode (DSMIV criteria).
Other factors that may influence the risk of relapse have been suggested in the literature
but have not been formally tested in prospective studies:
1. cognitive deficits: the existence of neuropsychological deficits in bipolar disorder
are well documented and their role in the risk of relapse is suspected. Yet the nature
of these deficits, their origin and their course remain poorly investigated. Indeed,
some appear to be related to the neurotoxicity of the episodes themselves, the other
being related to the vulnerability to bipolar disorder
2. The involvement of genetic vulnerability factors in bipolar disorder is widely
demonstrated. Several arguments suggest the implication of genetic factors in the risk
of relapse. This is the case for some outcome patterns such as rapid cycling or
antidepressants induced mania. Again, this has never been tested in cohorts followed
prospectively.
3. The role of certain inflammatory and infectious factors in the etiology of bipolar
disorder has been suggested but it is clear whether these biomarkers are "state" or
"traits". Thus, the role of neurotoxic inflammatory or infectious factors in relapse
mood has never been tested in a prospective follow up studies.
- Main objective of the project To determine if the scores of AIM and ALS, assessed
at baseline in euthymic bipolar patients is associated with relapse in patients
during a 2 years follow-up period.
- Secondary objectives of the project Determine if the neuropsychological
performance at T0, measured in euthymic patients predict relapse during a 2 years
follow-up period.
Determine whether the neuropsychological deficits observed in euthymic bipolar patients that
contribute to functional impairment worsen with time.
DNA collection to test the involvement of candidate genes Serum collection to study the
biological and infectious biomarkers
• Methodology Prospective follow up studies. Multicenter.
Status | Active, not recruiting |
Enrollment | 274 |
Est. completion date | December 2017 |
Est. primary completion date | August 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility |
Inclusion Criteria: - Bipolar disorder I or II - French language - Aging between 18 years and 55 years - Young Mania Rating Scale (YMRS) < 12 - Montgomery Asberg Depression Rating Scale (MDRS) < 10 Exclusion Criteria: - Rapid cycling - Undefined number of major relapses - Drug and alcohol abuse within 6 months - Electroconvulsive therapy (ECT) within 12 months - Epilepsy, traumatism cranial or other neurological diseases - Daltonism or visual trouble |
Country | Name | City | State |
---|---|---|---|
France | Fernand Widal Hospital | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Combined outcome based on AIM and ALS's score assessed at baseline in euthymic bipolar patients associated with relapse in patients during a 2 years follow-up period. | 24 months | ||
Secondary | Global neuropsychological performance based on combined score of all neuropsychological scales (detail below) at T0, measured in euthymic patients predict relapse during a 2 years follow-up period. | Neuropsychological scales : intellectual functioning, episodic verbal memory, processing speed, attention, working verbal memory, working visual memory, executive function | 24 months | |
Secondary | Global neuropsychological deficits based on combined score of all neuropsychological scales (detail below) observed in euthymic bipolar patients that contribute to functional impairment worsen with time | Neuropsychological scales : intellectual functioning, episodic verbal memory, processing speed, attention, working verbal memory, working visual memory, executive function | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT02855762 -
Targeting the Microbiome to Improve Clinical Outcomes in Bipolar Disorder
|
N/A | |
Recruiting |
NCT05915013 -
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
|
Phase 1 | |
Recruiting |
NCT05206747 -
Ottawa Sunglasses at Night for Mania Study
|
N/A | |
Completed |
NCT02513654 -
Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects
|
Phase 1 | |
Recruiting |
NCT06313918 -
Exercise Therapy in Mental Disorders-study
|
N/A | |
Completed |
NCT02304432 -
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine
|
Early Phase 1 | |
Recruiting |
NCT06197048 -
Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder
|
N/A | |
Completed |
NCT03497663 -
VIA Family - Family Based Early Intervention Versus Treatment as Usual
|
N/A | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Completed |
NCT02212041 -
Electronic Cigarettes in Smokers With Mental Illness
|
N/A | |
Recruiting |
NCT05030272 -
Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings
|
N/A | |
Recruiting |
NCT04298450 -
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
|
N/A | |
Active, not recruiting |
NCT03641300 -
Efficacy of Convulsive Therapies for Bipolar Depression
|
N/A | |
Not yet recruiting |
NCT04432116 -
Time and Virtual Reality in Schizophrenia and Bipolar Disorder
|
N/A | |
Completed |
NCT02970721 -
Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder
|
||
Terminated |
NCT02909504 -
Gao NARASD Lithium Study
|
Phase 4 | |
Terminated |
NCT02893371 -
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
|
||
Recruiting |
NCT03088657 -
Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study
|
||
Recruiting |
NCT02481245 -
BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study
|
Phase 2 |